# Investigating Patient Characteristics of Intermediate Stage Hepatocellular Carcinoma Patients Treated With Nexavar and Their Distribution to Different Treatment Groups as Well as Determining Effectiveness and Safety

> **NCT01908322** · — · COMPLETED · sponsor: **Bayer** · enrollment: 19 (actual)

## Conditions studied

- Carcinoma, Hepatocellular

## Interventions

- **DRUG:** Sorafenib (Nexavar, BAY43-9006)

## Key facts

- **NCT ID:** NCT01908322
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08
- **Primary completion:** 2015-06
- **Final completion:** 2015-09
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2015-11-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01908322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01908322, "Investigating Patient Characteristics of Intermediate Stage Hepatocellular Carcinoma Patients Treated With Nexavar and Their Distribution to Different Treatment Groups as Well as Determining Effectiveness and Safety". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01908322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*